home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630606.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
44 lines
Document 0606
DOCN M9630606
TI Treatment of refractory juvenile chronic arthritis by monoclonal CD4
antibodies: a pilot study in two children.
DT 9603
AU Horneff G; Dirksen U; Schulze-Koops H; Emmrich F; Wahn V; Department of
Paediatrics, University of Dusseldorf, Germany.
SO Ann Rheum Dis. 1995 Oct;54(10):846-9. Unique Identifier : AIDSLINE
MED/96097728
AB OBJECTIVE--To study the effect of anti-CD4 treatment in patients
suffering from refractory systemic onset juvenile chronic arthritis
(JCA). METHODS--Two children were treated with the mouse CD4 antibody
MAX.16H5. The effects on numbers of circulating CD4 T cells, clinical
symptoms and C reactive protein (CRP) level were studied and the
appearance of human antimouse immunoglobulin antibodies investigated.
RESULTS--In patient one, disappearance of fever and malaise and a
reduction of arthritic activity were observed together with a reduction
in CRP. When disease activity returned eight weeks later, a second
successful course of treatment was administered. It was possible to
reduce the corticosteroid dosage permanently. In the other child, a
first treatment cycle did not alter disease activity. A marked reduction
in clinical and laboratory disease activity markers was observed after
the second course. Only transient and mild side effects were observed.
One patient exhibited a short lasting febrile reaction with chills, the
other an urticarial rash. In both patients, human antibodies to mouse
immunoglobulin became detectable. The decrease in the number of CD4 T
cells in the peripheral blood was only short lasting and numbers
returned to normal values within one to eight weeks, even after the
second course of antibody treatment and under concomitant
immunosuppressive treatment. No sustained clinical remissions could be
achieved. CONCLUSIONS--These preliminary observations support the
evidence of positive effects of CD4 antibody treatment in refractory
systemic onset JCA. Long term efficacy, however, remains to be
established.
DE Adolescence Antibodies, Monoclonal/ADVERSE EFFECTS/*THERAPEUTIC USE
Antigens, CD4/*IMMUNOLOGY Arthritis, Juvenile
Rheumatoid/IMMUNOLOGY/*THERAPY Child CD4 Lymphocyte Count Female
Human Male Pilot Projects Severity of Illness Index Support,
Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).